| Overview |
| bs-11782R-Cy5 |
| PON3 Polyclonal Antibody, Cy5 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat, Dog |
| Specifications |
| Cy5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human PON3 |
| 201-300/354 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| Secreted, Extracellular matrix |
| paraoxonase 3; paraoxonase3; Pon3; PON3_HUMAN; Serum paraoxonase/lactonase 3; 2810004E20; AI786302; MGC95026. |
| Paroxon is an organophosphorus anticholinesterase compound, used topically in the treatment of glaucoma. It is produced in vivo in mammals by microsomal oxidation of the insecticide parathion. Parathion is inert until transformed to paroxon. Paroxonase or PON is an arylesterase that is capable of hydrolyzing paroxon to produce p-nitrophenol. PONs are nonspecific and their classification is based not only on substrate specificity but also on tissue distribution, inhibition properties and physicochemical characteristics such as electrophoretic mobility and molecular weight. In contrast to PON1, which is expressed mainly in the liver, PON2 is expressed in a variety of mouse tissues, including the pancreas. PON3 is a associated with the high density lipoprotein fraction of serum. The genes which encode PON1-3 are physically linked and map to human chromosome 7q21.3. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz